Tuesday☕️

Trending:
- Tesla Self Driving Capabilities
- ADHD Medication Side Effects
Markets:
- Yesterday’s U.S. stock market:

- Yesterday’s commodity market:

- Yesterday’s crypto market:

Tesla Self Driving Capabilities:
- The new FSD v12 update from Tesla marks a significant shift in how the vehicle's self-driving system operates. Previously, the vehicle controls for Tesla's self-driving features were hardcoded by engineers. This means that specific instructions and rules for driving behaviors were programmed into the system by developers.
- The car would respond to various driving scenarios based on these pre-set rules and algorithms. With the FSD v12 update, Tesla is transitioning to having these vehicle controls managed by neural networks. Neural networks are a form of artificial intelligence that mimic the human brain's way of processing information.
- They are capable of learning and making decisions based on data they receive. In the context of Tesla's self-driving cars, this means the system can continuously learn and adapt from vast amounts of data gathered from the driving environment. Instead of relying on fixed programming for making driving decisions, the car will now use advanced AI algorithms that can process real-time data, learn from new situations, and make decisions more like a human driver would.
- This allows for a more dynamic and adaptable self-driving system, which can potentially handle a wider range of driving scenarios more effectively than humans overtime. However, it's important to note that while this technology represents a significant advancement, the responsibility for driving still legally rests with the human driver, as the technology has not yet reached a stage where it can fully replace human judgment and control.
ADHD Medication Side Effects:
- In a significant study published in the JAMA Psychiatry journal, Swedish researchers have uncovered a correlation between the use of ADHD medications, such as Ritalin and Adderall, and an elevated risk of developing heart disease. The study methodically compared the incidence of heart conditions among individuals on these medications to those not using them.
- The findings indicated a clear trend: irrespective of age or initial health conditions, the longer the duration of ADHD medication use, the higher the likelihood of developing heart-related issues such as high blood pressure. While the study acknowledges the considerable benefits that ADHD medications offer, it also brings to light the importance of further investigation into their long-term effects.
- This aspect of the research underscores a critical need in the medical community to balance the effective treatment of ADHD with the potential cardiovascular risks that may arise from prolonged medication use. In light of these findings, the researchers suggest that it’s essential for healthcare providers and patients to be proactive in monitoring heart health, particularly in those undergoing long-term treatment with ADHD medications.
Statistic:
Top 50 largest pharmaceutical companies by market capitalization:
- 🇺🇸 Eli Lilly: $561.54B
- 🇩🇰 Novo Nordisk: $467.58B
- 🇺🇸 Johnson & Johnson: $364.17B
- 🇺🇸 Merck: $257.02B
- 🇺🇸 AbbVie: $245.56B
- 🇨🇭 Roche: $218.32B
- 🇨🇭 Novartis: $200.90B
- 🇬🇧 AstraZeneca: $197.72B
- 🇺🇸 Pfizer: $170.18B
- 🇺🇸 Amgen: $141.43B
- 🇫🇷 Sanofi: $119.49B
- 🇺🇸 Bristol-Myers Squibb: $99.74B
- 🇺🇸 Gilead Sciences: $93.35B
- 🇺🇸 Vertex Pharmaceuticals: $90.23B
- 🇺🇸 CVS Health: $88.46B
- 🇺🇸 Regeneron Pharmaceuticals: $86.94B
- 🇦🇺 CSL: $82.37B
- 🇺🇸 Zoetis: $82.08B
- 🇩🇪 Merck KGaA: $76.18B
- 🇬🇧 GlaxoSmithKline: $72.95B
- 🇯🇵 Chugai Pharmaceutical: $54.78B
- 🇯🇵 Daiichi Sankyo: $50.87B
- 🇯🇵 Takeda Pharmaceutical: $44.15B
- 🇨🇳 Jiangsu Hengrui Medicine: $41.87B
- 🇺🇸 Seagen: $40.45B
- 🇨🇳 WuXi AppTec: $35.23B
- 🇮🇳 Sun Pharmaceutical: $34.38B
- 🇩🇪 Bayer: $34.09B
- 🇺🇸 Biogen: $33.15B
- 🇺🇸 Moderna: $29.63B
- 🇳🇱 Argenx: $29.28B
- 🇨🇭 Lonza: $29.10B
- 🇮🇪 Horizon Therapeutics: $26.63B
- 🇺🇸 West Pharmaceutical: $26.18B
- 🇨🇳 WuXi Biologics: $25.14B
- 🇩🇪 BioNTech: $23.22B
- 🇮🇪 ICON plc: $22.17B
- 🇯🇵 Astellas Pharma: $21.78B
- 🇯🇵 Otsuka Holdings: $20.41B
- 🇩🇰 Genmab: $20.05B
- 🇺🇸 Alnylam Pharmaceuticals: $19.97B
- 🇨🇳 BeiGene: $19.69B
- 🇺🇸 Baxter: $18.47B
- 🇺🇸 LabCorp: $18.06B
- 🇰🇷 Celltrion: $17.56B
- 🇺🇸 Walgreens Boots Alliance: $17.37B
- 🇺🇸 BioMarin Pharmaceutical: $16.68B
- 🇬🇧 Royalty Pharma: $16.27B
- 🇯🇵 Eisai: $14.71B
- 🇧🇪 UCB: $14.50B
Article Links:


Thanks for reading!
TIME IS MONEY: Your Free Daily Scoop of Markets📈, Business💼, Tech📲🚀, and Global 🌎 News.
The news you need, the time you want.

Support/Suggestions Emails:
timeismoney@timeismon.news